Join to View Full Profile
241 Fletcher StEdison, NJ 08820
Phone+1 732-594-3736
Dr. Greaves is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Centers for Disease ControlVisiting Scientist, Epidemiology, 1980 - 1983
Vanderbilt University Medical CenterFellowship, Infectious Disease, 1979 - 1980- Mc Gill UniversityInternal Medicine Residency, 1976 - 1979
McGill University Faculty of MedicineClass of 1976
Certifications & Licensure
DC State Medical License 1997 - 2021
GA State Medical License 1982 - 1985
TN State Medical License 1979 - 1982
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Infectious Disease
Clinical Trials
- A Multicenter, Prospective, Randomized, Double-Blind, Placebo-Controlled Trial of Three Preparations of Low-Dose Oral Alpha Interferon in HIV-Infected Patients With CD4+ Counts >= 50 and <= 350 Cells/mm3
- Safety and Efficacy of Grazoprevir (MK-5172) + Elbasvir (MK-8742) in Participants With Chronic Hepatitis C and Chronic Kidney Disease (MK-5172-052) Start of enrollment: 2014 Mar 17
- Evaluation of the Safety and Efficacy of Reformulated Raltegravir (MK-0518) 1200 mg Once Daily in Combination With TRUVADA™ in Human Immunodeficiency Virus (HIV)-1 Infected, Treatment-Naive Participants (MK-0518-292) Start of enrollment: 2014 May 23
- Join now to see all
Publications & Presentations
PubMed
- 3 citationsDoravirine exposure and HIV-1 suppression after switching from an efavirenz-based regimen to doravirine/lamivudine/tenofovir disoproxil fumarate.Wayne Greaves, Hong Wan, Ka Lai Yee, Bhargava Kandala, Pavan Vaddady
Antimicrobial Agents and Chemotherapy. 2019-09-23 - 57 citationsSwitching to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) Maintains HIV-1 Virologic Suppression Through 48 Weeks: Results of the DRIVE-SHIFT Trial.Margaret Johnson, Princy Kumar, Jean-Michel Molina, Giuliano Rizzardini, Pedro Cahn
Journal of Acquired Immune Deficiency Syndromes. 2019-08-01 - 11 citationsEvaluation of Neural Tube Defects (NTDs) After Exposure to Raltegravir During Pregnancy.Hala Shamsuddin, Casey Raudenbush, Brittany L Sciba, Yun-Ping Zhou, T. Christopher Mast
Journal of Acquired Immune Deficiency Syndromes. 2019-07-01
Press Mentions
National Kidney Foundation Honors Merck with 2017 Corporate Innovator AwardApril 18th, 2017
Professional Memberships
- Member
- Infectious Diseases Society of America - IDSAMember
- Member
- National Medical Association - NMAMember
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
